Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Cited In for PubMed (Select 16179215)

1.

Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.

Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P.

Respir Res. 2013 Oct 7;14:100. doi: 10.1186/1465-9921-14-100.

2.

Pharmacotherapies for COPD.

Ejiofor S, Turner AM.

Clin Med Insights Circ Respir Pulm Med. 2013 Apr 25;7:17-34. doi: 10.4137/CCRPM.S7211. Print 2013.

3.

Ten years of tiotropium: clinical impact and patient perspectives.

Yohannes AM, Connolly MJ, Hanania NA.

Int J Chron Obstruct Pulmon Dis. 2013;8:117-25. doi: 10.2147/COPD.S28576. Epub 2013 Mar 15. Review.

4.

Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries.

Duborija-Kovacevic N, Martinovic M.

Multidiscip Respir Med. 2012 Jun 21;7(1):12. doi: 10.1186/2049-6958-7-12.

5.
6.

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.

Bleecker ER, Siler T, Owen R, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:431-8. doi: 10.2147/COPD.S21073. Epub 2011 Aug 18.

7.

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.

Beier J, Beeh KM.

Int J Chron Obstruct Pulmon Dis. 2011;6:237-43. doi: 10.2147/COPD.S7371. Epub 2011 Apr 12. Review.

8.

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.

Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G.

Respir Res. 2011 Apr 8;12:40. doi: 10.1186/1465-9921-12-40. Review.

9.

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis.

Van den Bruel A, Gailly J, Neyt M.

BMC Pulm Med. 2010 Sep 21;10:50. doi: 10.1186/1471-2466-10-50.

10.

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.

Neyt M, Devriese S, Thiry N, Van den Bruel A.

BMC Pulm Med. 2010 Sep 15;10:47. doi: 10.1186/1471-2466-10-47.

11.

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.

Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, Blatchford J, Pavia D, Hodder R.

Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:197-208.

12.

Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.

Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2010 Feb 18;5:41-53. Review.

13.

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.

Beeh KM, Hederer B, Glaab T, Müller A, Rutten-van Moelken M, Kesten S, Vogelmeier C.

Int J Chron Obstruct Pulmon Dis. 2009;4:119-25. Epub 2009 Apr 15.

14.

Safety, tolerability and risk benefit analysis of tiotropium in COPD.

Oba Y, Zaza T, Thameem DM.

Int J Chron Obstruct Pulmon Dis. 2008;3(4):575-84. Review.

15.

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis.

Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG.

BMC Med. 2009 Jan 14;7:2. doi: 10.1186/1741-7015-7-2.

16.

Tiotropium bromide.

Lipson DA.

Int J Chron Obstruct Pulmon Dis. 2006;1(2):107-14. Review.

17.

Role of tiotropium in the treatment of COPD.

Rice KL, Kunisaki KM, Niewoehner DE.

Int J Chron Obstruct Pulmon Dis. 2007;2(2):95-105. Review.

18.

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.

Barr RG, Bourbeau J, Camargo CA, Ram FS.

Thorax. 2006 Oct;61(10):854-62. Epub 2006 Jul 14. Review. Erratum in: Thorax. 2007 Feb;62(2):191.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk